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Survival after hematopoietic stem cell transplantation (HSCT) has improved and the number of allogeneic
HSCTs performed annually in the United States is expected to reach 10,000 by 2015. The National Marrow
Donor Program created the System Capacity Initiative to formulate mechanisms to care for the growing
number of HSCT recipients. One proposed method to increase capacity is utilization of pharmacists to manage
drug therapy via collaborative practice agreements (CPAs). Pharmacists have managed drug therapy in
oncology patients with CPAs for decades; however, there are limited HSCT centers that employ this practice.
Engaging in collaborative practice and billing agreements with credentialed pharmacists to manage therapeutic
drug monitoring, chronic medical conditions, and supportive care in HSCT recipients may be cost-effective and
enable physicians to spend more time on new or more complex patients. The goal of this paper is to provide
a framework for implementation of a CPA and address how it may improve HSCT program capacity.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Over 20,000 hematopoietic stem cell transplants (HSCT)
are performed in the United States each year [1]. The number
of HSCT procedures is expected to rise as a result of increased
utilization because of increased diversity and availability of
graft sources, improved supportive care, more frequent use
of reduced intensity regimens, and expanding indications
for HSCT [2]. Current projections forecast the number of
allogeneic HSCTs performed by 2015 will double compared
with 2010 [2,3]. Additionally, advances in transplantation
techniques and supportive care practices have improved
long-term survival after HSCT [4]. Health care providers
are exploring ways to expand the capacity to care for
the increasing number of HSCT recipients. Pharmacists are
key contributors to HSCT recipient care and are routinely
involved in therapeutic drug monitoring, managing adversedgments on page 517.
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12.12.022drug reactions, addressing drug interactions, providing
supportive care management, and conducting patient edu-
cation. Other processes pharmacists may facilitate to imp-
rove efﬁciency and HSCT patient capacity include responses
to prescription insurance prior authorization requests,
compliance with Risk Evaluation and Mitigation Strategies
programs, and medication requests from patient assistance
programs.
Drug therapy is one of the foundations of health care
delivery. Effective management of complex drug therapy
regimens and reduction in medication errors are essential.
According to the Institute of Medicine, medication errors
harm approximately 1.5 million patients in the United States
each year, resulting in over 3 billion dollars in medical
costs [5]. A multidisciplinary team approach that includes
pharmacists in the oncology setting has been shown
to signiﬁcantly reduce medication errors [5,6]. The use of
a collaborative practice agreement (CPA) is one avenue to
formalize clinical pharmacy practice as part of the multi-
disciplinary team. A CPA is formal partnership between
a pharmacist(s) and physician(s) that permits a pharma-
cist(s) to manage a patients’ medication therapy [7-10].Transplantation. Published by Elsevier Inc. All rights reserved.
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as this allows pharmacists to manage medication therapy
after a physician has established a diagnosis [11]. The ﬁrst-
published description of a formalized collaborative practice
between physicians and pharmacists was within the Indian
Health Service in the early 1970s [12,13]. Pharmacists have
utilized CPAs successfully in oncology for several decades
to manage supportive therapies, such as antiemetics and
colony-stimulating factors, as well as complications of mal-
ignancies and their treatment, including anemia, mucositis,
diarrhea, constipation, and pain (Table 1) [6,14-20]. Phar-
macists can help alleviate some of the burden created by the
demand for physicians to care for more patients by engaging
in CPAs and serving as “physician extenders” via medication
therapy management (MTM) visits [6]. MTM, a distinct
service designed to optimize therapeutic drug outcomes
for individual patients, does not require the development
of formal CPAs between an individual pharmacist(s) and
physician(s) [10].
One-third of allogeneic HSCT recipients and two-thirds of
autologous HSCT recipients are over the age of 50 [1]. Given
their increasing age, HSCT recipients require management
of not only their post-transplant medications but also
those indicated for pre-existing conditions. Allogeneic HSCT
recipients often take more than 15 medications, including
immunosuppressant, antimicrobial, anticoagulant, antihy-
pertensive, and hypoglycemic medications [21]. NumerousTable 1
Collaborative Practice Agreements between Pharmacists and Physicians in Hemato
Study Setting Measures
Chung C, et al.
2011 [19]
Oncology program in community
hospital
 Review chemotherapy orde
before/after implementation
of interdisciplinary program
 Dosing errors
 Schedule errors
Valgus J, et al.
2011 [6]
Adult outpatient oncology clinics
at university hospital
 Management of supportive
care by pharmacist/nurse te
 Education of cancer patients
 Improvement in efﬁciency
of infusion center
Shah S, et al.
2006 [18]
Hematology/oncology outpatient
clinic at Veterans Health
Administration clinic
 Documentation of pharmaci
driven: supportive care prov
drug-speciﬁc interventions,
number of prescriptions wr
between 11/1/2002 to
10/31/2003
 Number of patient visits
Bernstein B,
et al.
1999 [14]
Community hospital- oncology
service
 Pharmacy-based CSF protoc
which allowed pharmacist t
stop CSF when ANC
>1500 cells/mm3 x 2 days
after neutrophil nadir
Horne A, et al.
1997 [17]
Outpatient oncology clinic  Protocol for pharmacist
management of adjuvant
medications
Martin JK,
et al.
1988 [15]
Ambulatory care oncology clinic  Pharmacy management/
prescribing of antiemetics
ANC indicates absolute neutrophil count; CSF, colony stimulating factor.drug interactions must be managed and medication dose
adjustments are often required to ensure the avoidance of
drug misadventures in this population. The complexities of
the HSCT recipient makes the pharmacist uniquely suited to
support other practitioners to optimize patient’s medication
therapy. The goal of this paper is to provide a framework
for determining how to create and implement a formalized
CPA and how it may improve HSCT center capacity and
patient care.
CPA DEFINITION
A CPA involves a signed contract between a pharmacist(s)
and physician(s) permitting a pharmacist(s), in collaboration
with the prescriber(s), to select and modify medication
therapy indicated within that speciﬁed contract [7-9]. Phar-
macists may perform some or all of the following activities
under a CPA: patient assessment; initiate, adjust, or
discontinue drug therapy; order, interpret, and monitor
laboratory tests; formulate clinical assessments and develop
therapeutic plans; provide care coordination for wellness
and prevention of disease; and conduct essential patient
education [9]. Pharmacists can also facilitate research if they
are listed as an investigator on the protocol by utilizing a CPA
to order study-related medications and laboratory tests.
At the present time, 43 states have speciﬁc regulatory
authority for pharmacist-physician collaboration; 6 states do
not (Alabama, Delaware, Illinois, Kansas, Oklahoma, andlogy/Oncology
Outcomes Impact
rs  Cost savings (dose rounding
protocol) $120,000/year
 45% reduction (P < .0625) in
chemotherapy-related errors
 Positive
 Stronger relationships
between disciplines
and enhanced
communication
am
 Development of Supportive Care
Consultation Service led to
increase in patient encounters
from 43% preimplementation
to 77% postimplementation
 Pharmacist made 186 interventions
 Chemotherapy counseling service
led to >900 billable patient
education sessions over 18 months
 Developed rapid infusion protocol
for Rituximab
 Positive
 Improved supportive
care management
 Chemotherapy unit
more efﬁcient
 Standardized patient
education for patients
receiving new
chemotherapy regimens
st
ided,
itten
 423 patient visits
 342 supportive care issues
addressed
 308 drug speciﬁc interventions
 445 prescriptions written
 Positive
 Increased exposure of
pharmacists to patients
and other health care
providers
ol
o
 CSF discontinued by a pharmacist
32% of the time
 Cost savings of $22,416 for CSF
during ﬁrst 6 mo of protocol
initiation
 No effect on clinical efﬁcacy
 Positive
 Patient satisfaction survey with
51% response rate indicated patients
rated their satisfaction over 90% for
pharmacist performance counseling,
knowledge/professionalism, and
outpatient chemotherapy time
 Positive
 More than 1200 patients managed
(95% of patients in clinic)
 82% reported no emesis at 24-hour
follow-up call
 Positive
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Maine limits CPAs to emergency contraception [22].
The Centers for Medicare & Medicaid Services (CMS) recog-
nized pharmacists for the ﬁrst time as members of the
medical staff in the hospital setting on May 16, 2012 [23].
This landmark ruling allows payment for services when
qualiﬁed pharmacists perform all functions within their
scope of practice as permitted by state law, thus allowing
reimbursement for pharmacists to manage drug therapy
within a CPA. Some state laws allow practitioners to establish
CPAs in all practice environments, whereas others restrict
CPA utilization within an institution. Within institutions,
utilization of a CPA may vary among services and specialties.
Notably, each state has different regulations dictating the
roles and responsibilities in which a pharmacist may engage.
For example, some states may allow initiation of medication
therapy (independent prescribing) and others may only
allow modiﬁcation of existing drug therapy (dependent
prescribing) [24]. An organization must comply with the
pharmacy practice act of the state in which it resides
when developing a CPA; individual states may also include
educational prerequisites, allowable drug classes, quality
assurance, and documentation requirements in their regu-
lations that govern use of CPAs.
TYPES OF CPAS
CPAs may differ between institutions in the degree of
prescribing authority, minimum education and training
requirements, and documentation required. Most CPAs
are reviewed for renewal on an annual or biennial basis.
Selected examples of active CPAs within HSCT and some of
the differences between the current models are highlighted
in Table 2.
The Veterans Health Administration and the US Depart-
ment of Defense have the most comprehensive CPAs for
pharmacists [25]. Pharmacists with clinical privileges who
practice in Veterans Affairs Medical Centers (VAMCs) and the
Department of Defense are model representatives for clinical
pharmacy and have pioneered the progression and innova-
tion of the pharmacy profession. Qualiﬁed pharmacists at
VAMCs are designated as Clinical Pharmacy Specialists (CPS)
and usually have prescriptive authority within their scope of
practice. A CPS at the VAMC is deﬁned as a Master or Doctor
of Pharmacy who has completed a residency accredited by
the American Society of Health-System Pharmacists (ASHP)
and is board certiﬁed through the Board of Pharmaceutical
Specialties (BPS); or a pharmacist who has equivalent exp-
erience. The scope of practice for the CPS is approved by the
medical executive committee or similar, chief of staff, and
chief of pharmacy. The supervising physician authorizes the
CPS to prescribe and monitor drug therapy within speciﬁc
disciplines including, but not limited to diabetes, hyperten-
sion, infectious diseases and oncology. Routine CPS duties
under a CPA at a VAMC or in the Department of Defense often
include the following: responding to formal written
consultations for pharmacotherapy and pharmacokinetics,
taking medication histories, ordering and interpreting labo-
ratory tests, and writing prescriptions for patients with
chronic illnesses or for supportive care.
Some of the most unique CPA models are those in New
Mexico and North Carolina. New Mexico passed the Phar-
macist Prescriptive Authority Act in 1993, allowing qualiﬁed
pharmacists, designated as “pharmacist clinicians” by
the board, to enter into a CPA with physicians [26]. Pharma-
cist clinicians complete additional training in diagnosis andphysical assessment andmay then register for their ownDrug
Enforcement Administration number and apply for pres-
criptive authority under a supervising physician [27]. In North
Carolina, the Clinical Pharmacist Practitioner (CPP) Act bec-
ame effective in 2000, allowing qualiﬁed pharmacists to enter
into CPAswith a supervising physician(s) [28]. Applications to
become a CPP are reviewed and approved by both the North
Carolina state boards of pharmacy and medicine. The CPP
manages a patient’s drug therapy after the referring physician
has established a diagnosis, treatment plan, monitoring
parameters, and duration of therapy by way of protocols
developed at the treating facility. Any prescriptions written
by the CPP are in accordance with CPP regulations and are
provided for review by the supervising physician(s). CPPs are
also permitted to order laboratory tests needed to appropri-
ately manage a patient’s drug therapy.
BENEFITS OF A CPA
CPAs have been implemented for several disease states
including diabetes mellitus, anticoagulation, hyperlipidemia,
parenteral nutrition, heart failure, hypertension, smoking
cessation, immunization, asthma, and infectious diseases
and have generally resulted in positive patient outcomes
including improved health status and decreased preventable
drug-related problems [22]. Randomized controlled trials
involving pharmacist management via a CPA demonstrate
positive outcomes, including improved asthma control [29],
higher proportion of patients achieving cholesterol goals
[30,31], better blood pressure control [32,33], improved
glycated hemoglobin (HbA1c) [34,35], and improved inter-
national normalized ratio (INR) control and reduced bleeding
rates in patients taking warfarin [27,36].
CPAs between pharmacists and physicians have also been
established in the oncology setting. One such example is
at the University of North Carolina at Chapel Hill, where
a clinical pharmacy service was implemented in the insti-
tution’s outpatient hematology/oncology clinic [6,37]. The
pharmacist involved in the pilot program completed an
ASHP-accredited oncology pharmacy residency and was
a BPS board-certiﬁed oncology pharmacist and a CPP
approved by the North Carolina state boards of pharmacy
and medicine. The CPP identiﬁed 3 initial patient-related
goals: (1) manage patient supportive care; (2) develop and
provide standardized education to all patients receiving
complex chemotherapy regimens; and (3) improve efﬁciency
in the outpatient oncology infusion clinic by developing and
initiating a rituximab (Rituxan, Genentech, Inc., South San
Francisco, CA) rapid infusion protocol [6]. The CPP conducted
63 educational interviews over a 7-month period to provide
standardized verbal and written patient education about the
patients’ chemotherapy regimen, anticipated adverse effects,
and their management. The CPP was given the authority to
prescribe under physician supervision using agreed upon
protocols, leading to improvements in symptom scores on
a 5-point Likert scale for pain, nausea and constipation
[37,38]. Over 50% of the pharmacist interventions involved
antiemetic therapy; other common interventions included
resolving chemotherapy order errors and adjusting pain and
bowel regimens using predeﬁned algorithms. Initial analysis
of the ﬁrst 50 patients treated under the pharmacist-led
rituximab rapid infusion protocol identiﬁed a similar rate
of infusion reactions compared with patients treated per the
manufacturer’s recommendations and an average time
saving of 91 minutes per patient with the shorter infusion.
This initiative improved efﬁciency in the chemotherapy
Table 2
Examples of Current Collaborative Practice Agreements (CPA) in Stem Cell Transplantation
Institution and
Type of CPA
Primary Sponsors/Stakeholders Requirements Activities Drugs/Diseases Billing Structure Other Information
Duke University Medical
Center (Durham, NC)
 Facility (supervising
MDs)
 State (NC BOP)
 Federal
 CPP designation from NC BOP &
Medicine (based on education
and training/board
certiﬁcation)
 DEA registration if prescribing
controlled substances
Medication Management Most AHFS drug classes included
NOT authorized to order
 Schedule I controlled agents
 Chemotherapy
 Radiation therapy or
radiopharmaceuticals
N/A  Supervising or covering
MD(s) reviews and signs off
on all patient encounters
 CPP meets with supervising
MD(s) weekly to review
patient cases
Initiation and adjustment of
therapeutic and supportive
care medications
Labs/Diagnostics
Clinical Pharmacist
Practitioner (CPP)
Inpatient and Outpatient
 All lab tests needed for TDM
and pertaining to diagnosis
 Certain medical devices
Documentation
All activities documented in
medical record within 24 hours
University of North
Carolina, Chapel Hill
(Chapel Hill, NC)
 Facility (supervising
MDs and Pharmacy &
Therapeutics Committee)
 State (NC BOP)
 Federal
 CPP designation from NC BOP &
Medicine (based on education
and training/board
certiﬁcation)
 DEA registration if prescribing
controlled substances
Medication Management Most AHFS drug classes included
Commonly managed conditions
include:
 Anticoagulation
 Diabetes
 Immunosuppression
 Pain
 Vaccinations
NOT authorized to order
 Schedule I controlled agents
 Chemotherapy
 Radiation therapy or
radiopharmaceuticals
Facility fee
billing
 Supervising or covering
MD(s) reviews and signs
off on all patient encounters
Initiation and adjustment of
therapeutic and supportive
care medications
Labs/Diagnostics
Clinical Pharmacist
Practitioner (CPP)
Outpatient Only
Laboratory Tests relevant to
care and monitoring
Documentation
All activities documented in
medical record
MD Anderson Cancer
Center (Houston, TX)
 State (TX BOP)
 Facility (MDACC ECMS,
Division of Pharmacy,
supervising MDs)
 Clinical Pharmacy Specialist
 Completion of ASHP-accredited
PGY1 and/or PGY2 residency
 Each person goes through a
credentialing process
Medication Management Most AHFS drug classes included
NOT authorized to order
 Schedule I or II controlled
agents
 Chemotherapy
 Radiation therapy or
radiopharmaceuticals
N/A  Recredentialing is done
every yearMay sign medication orders to
order, adjust or discontinue
medications.
May call in outpatient
prescriptions as designated
agent of the physician
Labs/Diagnostics
DTM Protocol
Inpatient AND Outpatients
ﬁlling prescriptions at
MD Anderson Cancer
Center
Order diagnostic labs/test
pertinent to drug therapy
Documentation
All orders documented in the
medical record
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Thomas Jefferson
(Philadelphia, PA)
 Facility (supervising
MDs, Ofﬁce of Medical
Staff Affairs)
 State (PA BOP)
 Credentialing by facility with
clinical privileges
 Pharmacist must carry liability
insurance at a minimum of
$1million per occurrence
Medication Management Most AHFS drug class included N/A  Administration of certain
drugs or vaccines may be
permitted, but requires prior
authorization by PA BOP
 MD signs off on all orders
within 24 hours
Adjust medication doses,
frequencies, or routes
Labs/Diagnostics
DTM Protocol Order laboratory or other
diagnostic tests pertinent
to TDM
Documentation
All activities documented in the
medical record within 24 hours
The Hospital for Sick
Children (Ontario,
Canada)
 Facility (Medical
Directives Committee,
Medical Director,
Professional director,
responsible MDs)
 Member of Ontario College
of Pharmacists
 Pharmacy provider for BMT
patients
 Acknowledgement from
medical & pharmacy director
of pharmacist’s skills
 Institutional TDM certiﬁcation
Medication Management Speciﬁc drugs/drug cl ses
included:
 Antimicrobials
 Anticonvulsants
 Immunosuppressan
 Digoxin
 Lithium
 Methotrexate
 Salicylate
 Theophylline
 Acetaminophen
 Proton pump inhib rs,
ranitidine
 Octreotide
N/A
Dose adjustment of medications
requiring TDM, including
hepatic and renal adjustment
Labs/Diagnostics
Medical Directive
Inpatient only
Order and interpret laboratory
tests for TDM
Documentation
All activities documented in the
medical record the same day
Veterans Affairs Medical
Center
 Facility (pharmacy,
supervising MD, service
chief, Professional
Standards Board)
 State*
 Federal VHA (Directive
2009-014)
 Pharm.D. or M.S. from
ACPE-accredited SOP
 Completion of ASHP-accredited
residency
 Specialty BPS certiﬁed or
equivalent experience
Medication Management Most AHFS drug class included
Not authorized to init te
controlled substances ut may
renew agents already use (if
included in Scope of P ctice)
N/A  Supervising MD(s) periodically
assesses pharmacist’s care
 Various non-routine duties
may be approved if qualiﬁed,
such as phlebotomy or vaccine
administration
 Initiate, adjust, or discontinue
medications
 Perform limited physical
assessment for TDM
Labs/Diagnostics
Clinical Pharmacy
Specialist
Scope of Practice
Inpatient AND Outpatient
Order and interpret results of
noninvasive lab tests
Documentation
All activities documented in
medical record (preferably
within 24 hours)
ACPE indicates Accreditation Council for Pharmacy Education; AHFS, American Hospital Formulary Service; ASHP, American Society of Health-System Pharm ists; BMT, bone marrow transplantation; BOP, Board of Pharmacy;
BPS, Board of Pharmaceutical Sciences; CPA, collaborative practice agreement; CPP, clinical pharmacist practitioner; DCT, Department of Cellular Therapy; DEA rug Enforcement Agency; DTM, drug therapymanagement; ECMS,
Executive Committee Medical Staff; ICD-9, International Classiﬁcation of Diseases, Ninth Edition; MDACC, M.D. Anderson Cancer Center; N/A, not applicable GY, post-graduate year; TDM, therapeutic drug monitoring; VHA,
Veteran’s Health Administration.
* State of licensure for those who prescribe controlled substances.
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patient visits per week without additional resource expen-
ditures. This project demonstrated that the integration of
a CPP into the hematology/oncology clinic under a CPA
improved the supportive care management of cancer
patients, increased the efﬁciency of the chemotherapy infu-
sion unit, and standardized education to patients receiving
complex chemotherapy regimens [6].
There are currently no published reports documenting
utilization or outcomes of CPAs between a pharmacist and
physician in the HSCT population and only a small number of
HSCT centers have formal CPAs in place. The complexity
of drug therapy regimens in HSCT recipients makes utiliza-
tion of CPAs potentially beneﬁcial to both patients and
physicians in a number of ways. Pharmacist-physician col-
laboration via CPAs may free up physician and advanced
practice professional time and allow physicians to see more
patients, focus on more complicated diagnostic issues, and in
turn meet the demand of the increasing number of alloge-
neic HSCTs in the United States. Pharmacists also play an
integral role in necessary patient education to improve
medication adherence and understanding of medications
[39-41]. Some of the HSCT-speciﬁc therapy decisions
pharmacists could be involved in include initiating, moni-
toring and modifying medications that require therapeutic
drug monitoring; adjusting therapy for supportive care
needs; managing drug interactions; monitoring for and
treating transplant regimen-related toxicities and chronic
conditions (eg, hypertension, diabetes, hyperlipidemia);
ordering and interpreting laboratory tests pertinent to drug
therapy; creating, implementing, and guiding standardized
treatment algorithms; and providing patient education and
follow-up.Table 3
Representative Sections of a Collaborative Practice AgreementPROCESSES FOR IMPLEMENTING A CPA
Conduct a Needs Assessment
The initial step in implementing a CPA is conducting
a needs assessment for the speciﬁc institution to determine
what stakeholders identify as areas in need of improvement,
both in the current model and in the future with anticipated
increased numbers of allogeneic HSCT recipients. Physicians,
nurses, advanced practice professionals, pharmacists, patients,
and institution administrators should be queried to determine
how pharmacy services may be optimized to enhance patient
care. Providersmay identify patient care management aspects
that are labor intensive, such as therapeutic drug monitoring
for calcineurin inhibitors. MTM of comorbidities in the HSCT
setting, including dyslipidemia, hypertension, and diabetes,
may also be beneﬁcial where organ dysfunction and drug
interactionsmake pharmacotherapymore complex. Providers
may identify resolving insurance coverage gaps as a priority.
Patients may express concerns with cost of medications and
a desire to minimize the complexity of the regimen. Explain-
ing possible beneﬁts of a CPA and how itworks are essential to
the agreement’s success.I. Program overview
II. Purpose
III. Patient inclusion criteria
IV. Responsibilities
V. Monitoring and treatment guidelines
VI. CPA operating instructions
VII. Training requirements
VIII. Quality improvement
Adapted with permission from Practice Advisory on Collaborative Drug
Therapy Management by Academy of Managed Care Pharmacy [10].Evaluate Stafﬁng Constraints
A pharmacist may already practice in an environment
where implementing a CPA will not require additional
funding for a pharmacist position. A CPA may actually
improve efﬁciency by allowing for medication adjustments
without provider contact. In other settings, additional
pharmacy personnel may be needed to manage patients
via a CPA.Identify Training Requirements
The organization should determine which pharmacists
will practice within CPAs and what combination of creden-
tials, training, and experience is necessary for those phar-
macists [42,43]. Some requirements to consider for
pharmacists participating in a CPA in HSCT, in addition to
those required by the state the pharmacist practices in, may
include completion of an ASHP-accredited oncology phar-
macy residency, BPS board certiﬁcation in oncology phar-
macy, and completion of an institution-speciﬁc training
program. Some CPAs allow pharmacy residents to participate
under the supervision of a preceptor pharmacist or a physi-
cian; institutions that train pharmacy residents must address
how they will be utilized.Develop the CPA
Pharmacists and physicians should collaborate to develop
a CPA that beneﬁts HSCT recipients. Providersmay determine
that a CPA with a deﬁned protocol is most helpful. This may
include speciﬁc algorithms for management of selected
chronic medical conditions such as osteoporosis, diabetes,
dyslipidemia, or hypertension based on clearly deﬁned
decision criteria, or management of certain medications such
as immunosuppressive therapy, warfarin and/or vaccines.
Typical sections included in a CPA are described in Table 3.
Alternatively, a CPA may be more appropriate wherein
qualiﬁed pharmacistsworkingwithin the context of a deﬁned
protocol are permitted to assume professional responsibility
for performing patient assessments; ordering drug therapy-
related laboratory tests; administering drugs; and selecting,
initiating, monitoring, continuing, and adjusting drug regi-
mens [9]. Either type of agreement should bemutuallyagreed
upon by the collaborating physicians and pharmacists and
reviewed by an appropriate body responsible for quality
assurance within the clinician’s practice setting.
A CPA should clearly deﬁne the patient population, scope
of patient care, setting, and time frame to which the CPA
will apply. Patients may be seen either through referral to
the pharmacy service by another health care provider or by
deﬁned inclusion characteristics, such as all HSCT recipients
or those patients who meet speciﬁc criteria. The CPA may
allow for only therapeutic drug monitoring and adjustment
of calcineurin inhibitors or management of chronic medical
conditions, or it may be more generalized to cover most
HSCT-related medication needs. The CPA should deﬁne the
applicable patient setting (hospital, hospital-based outpa-
tients, clinic-based outpatients) and the time frame covered
(eg, only before 100 days post-HSCT or as long as the patient
remains on immunosuppression). Ambulatory patients
whomight beneﬁt most from pharmacist monitoring include
(1) patients on 5 or more medications, (2) patients receiving
at least 12 medication doses per day, (3) patients whose
medication regimen changed more than 4 times in the past
J.A. Merten et al. / Biol Blood Marrow Transplant 19 (2013) 509e518 51512 months, (4) patients with poor medication adherence, or
(5) patients on medications that require therapeutic drug
monitoring [44]. Finally, the CPA should identify criteria for
patient discharge from the pharmacist’s care (eg, patient no
longer on immunosuppression, patient is past a landmark
time point, patient no longer wishes to receive care).
The CPA should be reviewed and signed by all pharma-
cists and physicians who will practice under the agreement.
Other departments or governing bodies often need to review
and approve the CPA and are institution-speciﬁc, such as the
organization’s pharmacy and therapeutics committee, cre-
dentialing committee, legal department and/or hospital
administration.
Implement the CPA
Key elements of a successful CPA are described in Table 4.
The collaborative practice can begin after the CPA has been
developed and approved; however, a stafﬁng model for
patient care should ﬁrst be determined to allow for a smooth
transition and to ensure an efﬁcient practice. The pharmacist
should establish a regular location for patient encounters, the
frequency of patient visits, and plans for follow up (in person
or via telephone or internet). Amethod of scheduling patients
should be implemented; pharmacists can often employ the
same system used by other providers. The duration of patient
visits needs to be established, such as an initial visit of one
hour followed by subsequent visits of 15 to 30 minutes.
The pharmacist should document every patient en-
counter in the medical record including a complete medi-
cation list, medication adherence, pertinent laboratory
values, effectiveness and tolerability of therapy, medication
adjustments made, and treatment goals. Additional docu-
mentation is required if the pharmacist bills for services via
MTM. The documentation requirements for MTM are a time-
consuming aspect of billing for cognitive pharmacy services,
with one publication describing a median of 18 minutes
(range, 5 to 90) for documentation per visit [20].
Pharmacists and physicians should address potential
problems with implementation before initiating the CPA.
One possible barrier is the Social Security Act, in which CMS
deﬁnes physicians, nurse practitioners, and physician assis-
tants, but not pharmacists, as practitioners whose services
are eligible for Medicare Part B reimbursement. Therefore,
Medicare will not pay for prescription drug claims billed
under Medicare Part B for prescriptions written byTable 4
Key Elements for an Effective Collaborative Practice Agreement
Professional
relationship
An environment whereby one or more pharmacists
and one or more physicians have professional
relationships sufﬁcient to allow pharmacists under
a written and signed agreement to perform certain
patient care functions under prespeciﬁed conditions
Access Access to patients and pertinent information from
their medical record. Access to pertinent patient
laboratory tests and results
Competency Pharmacist knowledge, skills, and ability to perform
authorized functions
Communication Documentation and communication of pertinent
information in the patient’s medical record
Accountability Accountability for quality measures
Reimbursement Ability to be reimbursed for drug therapymanagement
activities
Resources Commitment of the time and resources necessary to
achieve stated goals and objectives
Adapted with permission from Practice Advisory on Collaborative Drug
Therapy Management by Academy of Managed Care Pharmacy [10].a pharmacist under a CPA and ﬁlled at a retail pharmacy. This
generally only applies to selected oral chemotherapy agents
and immunosuppressants. Medicare Part D prescription drug
sponsors must recognize a physicians’ authority to delegate
prescribing where authorized by state law [45]. There have
been previous unsuccessful attempts to amend the Social
Security Act to include pharmacists as eligible practitioners in
2004, 2008, and 2010 [42]. Other potential problems include
requests for pharmacists to provide services outside of the
scope of their CPA (eg, obtain prior authorization from
insurance companies for prescriptions written by other
providers or request medication from patient assistance
programs). Clear deﬁnitions of who is responsible for which
activities are necessary to ensure continuity of care, avoid-
ance of medication errors, and duplication of work. A third
possible barrier to implementation is physicians in some
settings who may have variable levels of conﬁdence in dele-
gating prescribing authority to pharmacists via a CPA [46].
MEASURING OUTCOMES OF CPAS
After a CPA is implemented, outcomes should be mea-
sured to determine the impact of the pharmacist(s). Outcome
measures for clinical pharmacy services should be com-
prehensive, accountable, scientiﬁcally sound, feasible, and
usable [47]. Data supporting pharmacist-directed outcomes
in HSCT have not been reported; however, there are publi-
cations in oncology that describe the development and
implementation of pharmacist-inclusive services in the areas
of supportive care, symptom management, and disease state
management [6,14,15,17-20,39,48]. The outcomes reported
in these studies vary widely, from raw data such as number
of patient visits and prescriptions written, to measured
endpoints such as cost savings and patient satisfaction.
A review of all of the above practice areas and measures
supports opportunities for pharmacists in the HSCT ﬁeld
to capture outcomes data from traditional acute and ambu-
latory care practice settings and collaborative practice-based
settings. Outcomes are usually deﬁned as clinical, economic,
or humanistic. Those potential outcomes that can be mea-
sured as a basis for pharmacist impact in HSCT are described
in detail in this section.
Clinical Outcomes
The gold standard of clinical outcomes data is improve-
ment in the clinical course of patients; however, it is also the
most challenging to capture and relate back to a single
intervention, such as a pharmacist’s involvement in care.
Changes in survival, duration of hospitalization, or presence
of graft-versus-host disease based on a single discipline’s
intervention are difﬁcult to measure in HSCT recipients
because of the complex andmultidisciplinary nature of HSCT
recipient care.
Surrogate outcomes
Surrogate markers have been previously documented to
indicate the impact on patient outcomes and may be used
by the pharmacist to measure impact of services. These
surrogates include rehospitalization rates, maintenance of
calcineurin inhibitor plasma levels within a predeﬁned
range, vaccination status post-HSCT, blood pressure or lipid
control, decrease in HbA1c in steroid-induced diabetes, and
INR maintenance in patients taking warfarin [49-53]. These
measures are known to impact the clinical course and
outcomes of HSCT recipients, and are outcomes that may be
positively impacted by pharmacist management.
J.A. Merten et al. / Biol Blood Marrow Transplant 19 (2013) 509e518516Medication adherence
Improved patient adherence to medication regimens and
post-transplant care is critical to achieving positive clinical
outcomes. Studies of patients with HIV, diabetes, and cancer
have demonstrated that pharmacists play an integral role in
patient adherence and understanding of their complex
medication regimens [39,54,55]. HSCT recipients, particularly
those receiving allogeneic HSCT, frequently take multiple
medications concurrently and the potential for clinically
signiﬁcant drug interactions is high. Adherence to a proper
medication regimen and schedule is vital to attain positive
outcomes in HSCT recipients. Adherence can be measured by
conducting patient interviews, tracking medication logs, and
counting pills. These simple tools can display the impact of
pharmacist education and counseling on patients’ under-
standing and adherence with their medications.
Provider compliance with guidelines and algorithms
Pharmacists have been involved in algorithm develop-
ment for oncology-associated conditions including anemia,
pain, use of colony-stimulating factors, and chemotherapy-
induced nausea and vomiting [6,14-17,56-57]. HSCT phar-
macists often participate in the development of critical
pathways and algorithms for standardized use of medication
therapy, including those employed for HSCT center accre-
ditation through the Foundation for the Accreditation
of Cellular Therapy. Noncompliance with treatment guide-
lines and algorithms can lead to adverse patient outcomes
[58,59].
Additionally, many HSCT programs are staffed by a variety
of disciplines with different backgrounds and training inc-
luding medical residents and fellows, nurses, and advanced
practice professionals. Creation of critical pathways and al-
gorithms in HSCT and evaluation of the impact and adher-
ence to those algorithms and guidelines can help maintain
consistency and uniformity in patient care.
Economic Outcomes
Some chronic diseases require close monitoring and
frequent medication dose adjustments; however, managing
these patients is not a cost-efﬁcient activity for physicians.
Engaging in CPAs with credentialed pharmacists may be
cost-effective and enable physicians and advance practice
professionals to spend more time on new or more complex
patients [42]. If pharmacist-based management of certain
chronic diseases and post-HSCT complications can save
providers time and allow them to provide higher-value
clinical services to a greater number of patients, this can
translate into not only cost savings but also possibly
increased revenue.
Pharmacists can also reduce costs to the institution by
selecting the most cost-effective therapy when several
equally effective options are available. HSCT programs often
have the most costly drug budgets and highest acuity of care
within an institution. Pharmacist involvement in cost
containment resulting from streamlined use of high-cost
medications, implementation of drug-use algorithms, and
formulary management are relatively easy outcomes to
measure.
Pharmacists can also bill for services in hospital-based
clinics using Current Procedural Terminology (CPT) Evalua-
tion and Management Codes 99211 to 99215, which can help
offset some of the expense of having a pharmacist care for
patients via CPAs [60]. A pharmacist can bill “incident to”
a physician in this practice setting using facility fee-onlybilling (no professional fee for the pharmacist services).
In one solid organ transplant setting, the utilization of
a pharmacist billing via facility fees increased billing by
approximately $100 per patient visit [60]. Pharmacists can
also bill “incident to” a physician in clinic-based outpatient
settings; however, this is at the lowest level of reimburse-
ment [61]. Alternatively, pharmacists can bill Medicare Part
D for clinic-based outpatients for cognitive services of MTM
via CPT codes 99605, 99606, and 99607 [20]. If a patient has
health insurance coverage other than Medicare Part D and is
a candidate for MTM services, the payer will need to be
contacted to determine if MTM services are covered, what
codes to use, and how to submit the claim. This may be
a challenging task, as HSCT centers have a high number of
patient referrals and encounter multiple insurance plans.
Each payer typically has it’s own criteria for patient eligibility
for MTM services and pharmacist requirements. Reim-
bursement rates range from 47% to 79% depending on the
insurance provider, in one publication of pharmacist-
provided MTM in oncology patients [20]. Reimbursement
through MTM CPT codes alone generally will not support the
entire salary for a pharmacist that manages outpatient HSCT
recipients with chronic conditions and high acuity. Accord-
ingly, HSCT pharmacists should measure and publish the
value of the services they provide to support future increases
in payment for cognitive services.Humanistic Outcomes
Patient satisfaction is a valuable and inﬂuential outcome.
Satisfaction with care leads to increased treatment referrals
and improved treatment adherence [62-64]. One study has
demonstrated that oncology pharmacists have a positive
impact on patient satisfaction [65]. Pharmacists working in
CPA-based HSCT clinics are in a position to see patients
regularly, as most patients have frequent follow-up before
and after transplantation. Pharmacist-provided continuity of
care from the inpatient to the outpatient setting may have
a positive impact on patient satisfaction.
Pharmacists practicing in CPA-based clinics can also have
a sustained and signiﬁcant impact on provider satisfaction.
Providers’ perceptions of specialty pharmacy services in
numerous acute care and ambulatory care settings have been
positive [46,66]. Satisfaction from these services was derived
from the provision of novel pharmacy services as well as
managing issues that can be burdensome for providers,
including therapeutic drug monitoring, medication recon-
ciliation, and insurance coverage issues. HSCT recipients
are often prescribed medications requiring therapeutic drug
monitoring, prior insurance authorization, specialty phar-
macy dispensing, or compliance with Risk Evaluation
and Mitigation Strategies programs. Pharmacist manage-
ment of these aspects of care may positively impact provider
satisfaction.
Clinical, economic, and humanistic outcomes of CPA-
based pharmacy practice in HSCT can be measured using
a variety of tools as described. The type and extent of
such outcome measurements rely greatly on endorsement
of pharmacist collaborative drug therapy management from
the health care system and the transplant team. The phar-
macist must appropriately gauge their resources and ability
to track outcomes, as any endeavor to measure outcomes
can only be successful if the correct endpoints are measured
consistently and accurately.
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There is aprojected shortageof health careproviders in the
HSCT setting and a multidisciplinary, collaborative approach
to patient care is crucial [3]. Pharmacists have the knowledge
base and skills to assist physicians and advanced practice
professionals with drug therapy management. Most states
have passed legislation or revised their state medical and
pharmacy practice acts authorizing pharmacists to provide
care under CPAs. Implementation of a CPA may improve the
capacity to care for the expected future increase in HSCT
recipients. Facilities that implement pharmacist-provider
CPAs to assist in the care for HSCT recipients should docu-
ment and publish their outcomes supporting this practice,
which will enable others to justify adoption of this process.ACKNOWLEDGMENTS
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